Business Wire—Organ Recovery Systems’ LifePort Liver Transporter Preserves First Livers for Transplant as Part of the PILOT Continued Access Study

LifePort Liver Transporter has not been cleared or approved by FDA, and the safety and effectiveness of the LifePort Liver Transporter has not been established. LifePort Liver Transporter is not available for sale within the United States.

We are proud to announce that the first livers have officially been transplanted using the LifePort®Liver Transporter as part of the PILOT™ Continued Access Study. The first livers preserved with the LLT under Continued Access were transplanted at University Hospital in Newark, NJ. Rutgers New Jersey Medical School is the first of a larger effort to further investigate the benefits of integrating LLT into existing transplant programs at participating medical centers.

 

“I am extremely excited to finally be able to use oxygenated HMP for my patients as a targeted intervention to improve logistics, outcomes, and access to transplant by safely facilitating the use of Extended Criteria and DCD livers,” said Dr. James V. Guarrera.

Business Wire is a trusted source for news organizations, journalists, investment professionals and regulatory authorities, delivering news directly into editorial systems and leading online news sources via its multi-patented NX network.

Tagged In:

The Latest

Check out the most recent posts

Santiago, Strategic Account Manager

Santiago, Strategic Account Manager

I first joined Organ Recovery Systems in 2023 as Business and Development Manager for Spain and Portugal; today, I’m a Strategic Account Manager for Iberia. While I’ve always worked in various business development positions within healthcare, transplantation is a...

Katie, Strategic Account Manager

Katie, Strategic Account Manager

My connection to donation and transplantation began with my uncle’s heart transplant in 2002. Since 2011, I’ve served the field through roles in organ procurement, transplant nursing, service line leadership, and industry support for diagnostics and immunosuppressive...